The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 30, 2014

Filed:

Jul. 19, 2012
Applicants:

Dennis J. Paul, New Orleans, LA (US);

Harry J. Gould, New Orleans, LA (US);

Inventors:

Dennis J. Paul, New Orleans, LA (US);

Harry J. Gould, New Orleans, LA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 31/425 (2006.01); A61K 31/335 (2006.01); A61K 31/35 (2006.01); A61K 31/21 (2006.01); A61K 31/045 (2006.01); A61K 31/7048 (2006.01); A61K 31/704 (2006.01); A61K 31/4375 (2006.01); A61K 45/06 (2006.01); A61N 1/36 (2006.01); A61N 1/04 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 31/704 (2013.01); A61K 31/4375 (2013.01); A61K 45/06 (2013.01); A61N 1/36 (2013.01); A61N 1/0456 (2013.01); A61N 1/0452 (2013.01);
Abstract

A targeted osmotic lysis (TOL) of tumor cells that over-express voltage-gated sodium channels (VGSCs) has been developed that uses a combined therapy of a drug that blocks sodium, potassium-adenosine triphosphatase (Na, K-ATPase) that is then followed by an activation of VGSCs, for example, by electrical or pharmacological stimulation. Activation of VGSCs conducts sodium into the cancer cells in much greater amounts than non-cancer cells. Water follows this sodium gradient into the cancer cells, causing swelling and lysis. Because non-cancerous cells do not over-express VGSCs, less sodium and less water will enter the cells, and the non-cancerous cells will not lyse. This method is applicable to all cells that over-express VGSCs, including, but not limited to, highly invasive breast cancer, prostate cancer, small cell lung cancer, non-small cell lung carcinoma, lymphoma, mesothelioma, neuroblastoma, and cervical cancer.


Find Patent Forward Citations

Loading…